# Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease

> **NCT00224263** · PHASE2 · COMPLETED · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 360 (—)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Lingzhi (Ganoderma)

## Key facts

- **NCT ID:** NCT00224263
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2008-02
- **Target enrollment:** 360 (—)
- **Last updated:** 2011-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00224263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00224263, "Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00224263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*